Why the study?
Does dofetilide improve pharmacological defibrillation in patients with atrial fibrillation within 1 week of onset compared to class I antiarrhythmic agents?
Does dofetilide improve pharmacological defibrillation in patients with atrial fibrillation within 1 week of onset compared to class I antiarrhythmic agents?
Intravenous dofetilide is effective for the pharmacological cardioversion of recent-onset atrial fibrillation, with its efficacy being highly dependent on a shorter duration of the arrhythmia.
May support dofetilide cardioversion in short-duration AF; leaves open randomized comparisons to class I agents.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Kobayashi et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: